MRI in Staging Ovarian Cancer Using MRI Contrast Agent

Ovarian Cancer Clinical Trial

Official title:

Værdien af MRI Til Staging af c.Ovarii-et Prospektivt Studie

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT00463996
• Other study ID #: MR-Center-001
• Status: Not yet recruiting
• Phase: N/A
• First received: April 18, 2007
• Last updated: April 18, 2007
• Start date: April 2007
• Est. completion date: April 2008

Study information

• Verified date: April 2007
• Source: University of Aarhus
• Contact: Liselotte Ibsen, doc
• Phone: +4589495201
• Is FDA regulated: No
• Health authority: Denmark: Ethics Committee
• Study type: Observational

Clinical Trial Summary

Can MRI be used to stage ovarian cancer?

Description:

Staging of ovarian cancer can best be performed with CT or MRI compared to ultrasound. Studies have shown an increase in pos. predictive value by adding contrast i.v. to the MR-examination protocol. We compare staging of ovarian cancer by 1.MRI without contrast (standard method) to 2.MRI with contrast agent i.v. (new method)in the same patient. Golden standard are findings at operation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: April 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• suspicion of ovarian cancer

Exclusion Criteria:

• recurrence of disease

• contraindication to MRI, contrast agent

• inoperable patients for other reasons

Study Design

Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal

Related Conditions & MeSH terms

• Ovarian Cancer
• Ovarian Neoplasms

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Aarhus